RPG Life Sciences Lines Up Larger API Acquisitions With More Than ₹500 Crore of Available Capital
RPG Life Sciences is preparing for a larger round of active pharmaceutical ingredient acquisitions after completing two API transactions worth ₹215 crore in just over a month, with the company now holding more than ₹500 crore of available capital to expand manufacturing, complex chemistry capabilities and international market access.
Managing Director Ashok Nair said the company is actively evaluating acquisition opportunities that could strengthen its API business through:
differentiated chemistry,
larger manufacturing capacity,
regulatory approvals,
and:
export capabilities.
The strategy follows RPG Active Pharma's recent acquisitions of:
Actis Generics for ₹80 crore
and the API and intermediates business of:
Raghava Life Sciences for up to ₹135 crore.
Together, those transactions have already transformed the scale of RPG's API platform.
Manufacturing capacity has increased from approximately:
110 kilolitres to 505 kilolitres,
while the commercial product portfolio has expanded from:
14 products to 45.
The customer base has grown from:
123 to more than 250,
and employee strength has increased from:
217 to more than 500.
RPG Life Sciences now intends to use its remaining capital to build a larger independent API and advanced-intermediates business serving third-party pharmaceutical customers in India and overseas.
RPG Life Sciences Has More Than ₹500 Crore Available
The company has indicated that it currently has:
more than ₹500 crore
available for further deployment.
RPG Life Sciences has entered an expansion phase supported by a committed capital infusion of:
₹700 crore.
After approximately ₹200-215 crore of recent acquisition commitments, management wants to deploy much of the remaining capital over roughly:
the next 12 months.
The funds could support:
additional acquisitions,
manufacturing expansion,
product development,
and regulatory approvals.
The company is not targeting a predetermined number of acquisitions.
Instead, management has said future transactions will depend on:
strategic fit,
valuation,
integration readiness,
and expected returns.
Larger API Assets Are Now Under Evaluation
RPG Life Sciences is no longer looking only at relatively small bolt-on transactions.
Following the Actis and Raghava acquisitions, the company is now evaluating:
larger API assets.
The next targets are expected to provide more than manufacturing capacity alone.
Management is looking for businesses capable of strengthening capabilities in areas such as:
complex chemistry,
regulated-market access,
high-value products,
customer relationships,
and export markets.
This reflects a shift from simply expanding production toward building a more complete pharmaceutical-ingredients platform.
USFDA-Approved Capabilities Are Part of Strategy
One area RPG is evaluating is:
US Food and Drug Administration-approved manufacturing capability.
Access to a USFDA-approved plant can make it easier for an API manufacturer to serve pharmaceutical customers targeting the US market.
However, management has stressed that regulatory approval by itself will not justify an acquisition.
RPG wants the economics of the underlying business to make sense.
The company will assess:
chemistry capabilities,
product portfolio,
customer base,
capacity utilisation,
and returns
alongside regulatory status.
RPG Is Not Building an API Business Only for the US
Although USFDA capability is part of its longer-term strategy, RPG's international ambitions extend beyond:
the United States.
The company is targeting broader regulated and emerging markets.
That approach could reduce dependence on one geography while widening the pool of potential pharmaceutical customers.
Export expansion can also help API manufacturers improve the revenue potential of facilities that have already received international regulatory approvals.
Two Acquisitions Completed in Five Weeks
RPG's current expansion has accelerated rapidly.
Through its API subsidiary:
RPG Active Pharma Limited,
the company completed or agreed two acquisitions within approximately five weeks.
The first was:
Actis Generics
for approximately:
₹80 crore.
That transaction was announced on:
July 29, 2026.
RPG then agreed to acquire the API and intermediates business of:
Raghava Life Sciences
for up to:
₹135 crore.
The combined consideration is approximately:
₹215 crore.
Raghava Deal Adds 300 KL of Capacity
The Raghava acquisition provides RPG with a manufacturing facility near:
Hyderabad
with approximately:
300 kilolitres of installed API capacity.
The facility carries:
European Union Good Manufacturing Practice approval
and:
World Health Organization GMP approval.
It also has regulatory credentials including:
Certificates of Suitability,
EU Written Confirmation,
and:
Korean Drug Master File approvals.
These approvals can support expansion into regulated international markets.
Raghava Adds 22 Commercial APIs
The Raghava business brings approximately:
22 commercialised APIs
and another:
seven products under development.
This immediately widens RPG Active Pharma's product portfolio.
An API platform with a broader product basket can potentially serve more customers and reduce dependence on a small number of molecules.
It also gives commercial teams more opportunities to deepen relationships with existing pharmaceutical customers.
Actis Generics Was First Step in Buy-and-Build Strategy
The earlier Actis Generics acquisition formed the first major step in RPG's:
buy-and-build API strategy.
Rather than relying entirely on organic expansion, the company is acquiring businesses that can add:
capacity,
products,
customers,
and technical capabilities
more quickly.
The Raghava transaction followed the same strategy.
Management has indicated that further acquisitions are expected to continue this platform-building approach.
API Capacity Has Nearly Quintupled
The two recent transactions have dramatically changed RPG Active Pharma's manufacturing scale.
Capacity has increased from approximately:
110 KL
to:
505 KL.
That represents an increase of nearly:
five times.
Manufacturing scale is important in APIs because customers increasingly seek suppliers capable of delivering:
consistent quality,
large volumes,
regulatory compliance,
and reliable long-term supply.
A larger platform can therefore improve RPG's ability to compete for bigger contracts.
Product Portfolio Expands From 14 to 45
The company's API product portfolio has expanded from:
14 products
to approximately:
45.
This creates much greater diversification.
A wider portfolio can reduce reliance on a limited number of commercial products and provide more opportunities across:
therapeutic categories,
geographies,
and customers.
It can also help RPG use manufacturing assets more efficiently by running multiple products across available capacity.
Customer Base More Than Doubles
RPG Active Pharma's customer base has expanded from:
123
to more than:
250.
Customer diversification is strategically important.
API businesses can become vulnerable if a large percentage of sales is concentrated among only a few pharmaceutical customers.
A broader client base can improve:
revenue resilience,
cross-selling opportunities,
and geographic diversification.
It can also create a stronger foundation for launching newly developed molecules.
Employee Base Climbs Above 500
The enlarged API platform now employs more than:
500 people.
That compares with approximately:
217 employees
before the recent transactions.
The increase reflects not only additional manufacturing capacity but also greater capabilities across:
research,
quality,
regulatory affairs,
operations,
and commercial functions.
Successfully integrating those teams will be an important part of RPG's next stage.
R&D Pipeline Expands to 28 Products
The company's development pipeline has also expanded significantly.
RPG's API research and development pipeline has increased from approximately:
12 products
to:
28.
A stronger pipeline is important because API businesses need a steady flow of new products to sustain growth.
Existing molecules can face:
pricing pressure,
competition,
and maturity.
New APIs and advanced intermediates can provide higher-growth opportunities.
Raghava Facility Is Significantly Underutilised
A major near-term opportunity lies within the Raghava plant itself.
Management has indicated that the approximately:
300 KL facility
is currently:
substantially underutilised.
That means RPG may be able to generate meaningful additional revenue without immediately spending heavily on major new construction.
Increasing utilisation can improve:
asset productivity,
operating leverage,
and returns on invested capital.
Raghava Plant Could Support ₹200 Crore Revenue
RPG believes the Raghava facility could potentially support approximately:
₹200 crore of annual revenue
at higher utilisation.
Importantly, management believes much of that growth can be achieved without:
significant incremental capital expenditure.
The company plans to improve utilisation through:
new customers,
new geographies,
product expansion,
and integration with its existing API operations.
That creates a potential route to improve returns from the acquisition relatively quickly.
Actis and Raghava Generated ₹70 Crore in FY26
Together, Actis Generics and the Raghava API business generated approximately:
₹70 crore of revenue in FY26.
RPG believes there is significant room to scale that base.
The opportunity therefore lies not only in acquiring existing earnings.
It also involves improving the acquired assets through:
greater utilisation,
expanded sales,
and operational integration.
This is central to the economics of the company's buy-and-build strategy.
RPG Active Pharma Will Operate as Independent Merchant API Business
RPG Active Pharma is being developed primarily as an:
independent merchant API and advanced-intermediates business.
It is not intended to function mainly as a captive supplier to RPG Life Sciences' own formulations portfolio.
That distinction significantly expands the addressable market.
RPG Active Pharma can sell products to:
third-party pharmaceutical companies
rather than depending only on internal demand.
Third-Party Customers Represent Larger Opportunity
Management sees external customers as the bigger growth opportunity.
The platform will target:
domestic pharmaceutical companies,
international customers,
regulated markets,
and selected contract-development opportunities.
This creates a different growth model from a captive API unit.
The business can expand based on the wider pharmaceutical industry's demand rather than being limited by the size of RPG Life Sciences' formulations operations.
CDMO Opportunities Could Become Additional Growth Driver
RPG is also evaluating selected opportunities in:
contract development and manufacturing organisation services.
CDMO businesses work with pharmaceutical companies to develop or manufacture molecules on their behalf.
This can create longer-term customer relationships and potentially higher-value revenue streams.
Successful CDMO platforms typically require:
strong chemistry skills,
regulatory reliability,
development expertise,
and consistent manufacturing execution.
The company's acquisition strategy can help build those capabilities.
Global Drugmakers Are Diversifying Supply Chains
RPG's API expansion coincides with a broader shift in pharmaceutical supply chains.
Global drugmakers are increasingly seeking to diversify sourcing beyond:
China.
The objective is often referred to as:
China-plus-one
or broader supply-chain diversification.
Pharmaceutical companies want to reduce excessive concentration risk and ensure continuity of supply.
India is one of the markets positioned to benefit because it already has:
large-scale pharmaceutical manufacturing,
chemistry expertise,
and regulatory experience.
India Has Opportunity to Gain API Market Share
India is already a major producer of generic medicines.
However, parts of its pharmaceutical industry continue to rely on imported:
APIs,
key starting materials,
and intermediates.
Building more domestic API capacity can therefore serve two strategic objectives.
It can support:
Indian pharmaceutical supply-chain resilience
while also creating:
export opportunities.
Companies with internationally approved facilities can target both objectives simultaneously.
RPG Wants More Than Commodity API Capacity
Management's acquisition criteria suggest the company is not interested merely in accumulating:
commodity manufacturing capacity.
Instead, it is seeking:
differentiated chemistry
and:
higher-value capabilities.
This matters because commodity APIs can face intense price competition.
More specialised molecules can potentially offer:
better margins,
stronger customer relationships,
and higher barriers to entry.
The quality of acquired capabilities may therefore matter more than absolute capacity.
Regulatory Access Can Increase Asset Value
In pharmaceutical manufacturing, capacity is valuable only if customers are permitted to use it.
Regulatory approvals therefore play an important role in an API facility's commercial potential.
An internationally accredited plant can potentially access:
Europe,
the United States,
Korea,
and other regulated markets
depending on its approvals and product filings.
This gives RPG a reason to prioritise regulatory credentials in future acquisitions.
InvAscent Backs RPG Active Pharma Expansion
RPG's API expansion is also supported by healthcare-focused private-equity investor:
InvAscent.
The company previously announced that funds managed by InvAscent would invest up to:
₹243 crore
initially in RPG Active Pharma.
The broader agreement envisages investments of up to approximately:
₹700 crore
from RPG Life Sciences and InvAscent in tranches.
This capital structure gives the API platform resources to pursue both organic and inorganic growth.
API Business Has Been Carved Into Separate Subsidiary
RPG Life Sciences has been restructuring its API activities into:
RPG Active Pharma.
The separation creates a more focused business platform.
A standalone subsidiary can have:
its own growth strategy,
dedicated capital,
specialist management,
and acquisition programme.
It also makes it easier to bring an external investor such as InvAscent directly into the API business.
Separate Platform Could Accelerate Decision-Making
A focused subsidiary can potentially move faster when evaluating acquisitions.
Instead of competing internally with formulations for:
capital
and:
management attention,
the API business can pursue its own strategic roadmap.
This is particularly useful when the company intends to complete several acquisitions over a relatively short period.
The structure also creates clearer financial accountability for the API platform.
RPG Life Sciences Remains Debt-Free
Management has indicated that RPG Life Sciences remains:
debt-free.
That gives the company greater flexibility as it pursues acquisitions.
A debt-free balance sheet can allow management to choose among:
internal cash,
equity capital,
partner investment,
and debt
depending on the economics of future transactions.
It also reduces the risk of excessive leverage during an aggressive acquisition phase.
₹500 Crore Could Be Deployed Within 12 Months
RPG expects to deploy roughly:
₹500 crore
of remaining capital over approximately:
the next 12 months
if suitable opportunities emerge.
The timeline indicates that management intends to move quickly.
However, the company has emphasised that it will not complete transactions simply to meet an acquisition target.
Each deal must satisfy criteria around:
fit,
valuation,
integration,
and returns.
That discipline will be important because rapid M&A can destroy value if assets are purchased at excessive prices.
Acquisitions Can Accelerate Growth but Increase Integration Risk
RPG's strategy offers speed.
Buying existing plants and businesses can add:
capacity,
people,
customers,
and products
much faster than building entirely new facilities.
However, acquisitions also create integration challenges.
The company must align:
quality systems,
technology,
employees,
regulatory processes,
commercial teams,
and operating procedures.
Completing several transactions within a short period makes that challenge more complex.
Quality Systems Are Critical in API Integration
Pharmaceutical manufacturing cannot be integrated like a conventional industrial business.
Every facility operates under detailed:
quality,
documentation,
and regulatory systems.
Changes must be carefully managed because deficiencies can affect:
customer approvals,
regulatory inspections,
and product supply.
RPG will therefore need to preserve compliance while pursuing operating efficiencies.
Export Growth Is Central to API Strategy
International business is expected to become a major component of RPG Active Pharma's growth.
The company wants acquired assets to improve:
regulatory access
and:
export capabilities.
Export markets can provide:
larger customer opportunities,
currency diversification,
and potentially stronger economics for differentiated products.
However, they also expose companies to more demanding regulatory and quality requirements.
Europe Is Already Supported by Raghava Credentials
The Raghava acquisition gives RPG additional credentials relevant to:
European markets.
Its facility is:
EU-GMP approved
and possesses regulatory documentation including:
Certificates of Suitability.
Those capabilities can help support API supplies to pharmaceutical companies operating within European regulatory frameworks.
This gives RPG a foundation on which to build broader overseas revenue.
US Market Remains Longer-Term Opportunity
The United States remains strategically attractive because of the size of its pharmaceutical market.
USFDA-approved capabilities could allow RPG Active Pharma to participate more deeply in supply chains for:
US generic and specialty pharmaceutical companies.
However, management's cautious approach suggests the company will not pursue a USFDA facility at any price.
The acquisition must provide a commercially viable combination of:
regulatory status,
products,
customers,
and utilisation.
Manufacturing Footprint Is Becoming Central to Growth
RPG's expansion strategy reflects the renewed importance of:
manufacturing scale.
For years, many Indian pharmaceutical companies focused heavily on formulation brands and finished products.
Global supply-chain changes have increased the strategic value of:
API manufacturing,
intermediates,
and chemistry capabilities.
Companies able to combine these capabilities with regulatory access can occupy a more important position in global drug supply chains.
API Expansion Supports RPG’s Wider Revenue Ambition
RPG Life Sciences has set a longer-term ambition of reaching approximately:
₹2,000 crore to ₹2,500 crore in revenue by 2030.
Expansion of the API business is expected to contribute to that growth.
The strategy also includes development of the company's domestic formulations portfolio and international business.
Acquisitions therefore form one component of a wider company-level expansion programme.
Company Has Been Investing in Modern Manufacturing
RPG Life Sciences has already invested approximately:
₹140 crore
in plant capital expenditure since FY22.
Those investments have supported modern manufacturing facilities carrying approvals across several international regulatory frameworks.
The current acquisition programme builds on that foundation.
Rather than relying solely on incremental capital expenditure, RPG is now using M&A to accelerate the scale-up.
Buy-and-Build Strategy Could Create Larger API Platform
The underlying objective is to create a:
scaled integrated API business.
A buy-and-build strategy typically begins with a core platform and then adds complementary assets.
Each acquisition may contribute a different strength.
One target could add:
capacity.
Another could add:
complex chemistry.
A third might provide:
USFDA approval
or:
international customers.
Over time, those pieces can create a business that is more valuable than the individual assets separately.
Cross-Selling Could Improve Revenue Potential
RPG's expanded customer base creates opportunities for:
cross-selling.
Customers acquired through Actis could potentially purchase products originating from Raghava.
Raghava customers could be introduced to RPG's existing APIs.
The larger 45-product portfolio therefore becomes more powerful when combined with a customer base exceeding 250.
Effective cross-selling could help raise utilisation at acquired facilities.
Larger Scale Can Improve Operating Economics
API manufacturing has meaningful fixed costs related to:
plants,
quality systems,
regulatory teams,
and R&D.
As utilisation increases, those costs can be spread across greater production volumes.
This can improve:
operating leverage
and potentially:
profitability.
That is one reason RPG is focused on filling unused capacity at the Raghava facility rather than immediately building additional greenfield capacity.
Product Development Will Remain Important
Acquisitions alone cannot sustain long-term growth.
RPG must continue launching:
new APIs
and:
advanced intermediates.
The expansion of its R&D pipeline to 28 products gives it a stronger base.
Management has previously indicated an ambition to develop multiple new APIs each year.
Successful commercialisation of those products will determine how effectively the company converts additional manufacturing capacity into revenue.
Customer Qualification Can Take Time
API manufacturers cannot always begin supplying a new customer immediately.
Pharmaceutical customers often require:
technical evaluation,
quality audits,
validation,
and regulatory filings
before approving a new supplier.
This means export growth may take time even when manufacturing capacity already exists.
RPG's existing customer base and acquired regulatory credentials can help shorten that process, but execution remains important.
Larger Acquisition Could Transform API Revenue Base
A further sizeable acquisition could materially change RPG Active Pharma's scale again.
The business has already moved from:
110 KL to 505 KL
of manufacturing capacity in a matter of weeks.
Deploying another ₹500 crore into strategically selected assets could potentially add:
new plants,
regulated-market credentials,
products,
or customers.
The API subsidiary could therefore look significantly different within the next year if management executes its plan.
Valuation Discipline Will Be Critical
The availability of capital does not automatically make every acquisition attractive.
Pharmaceutical manufacturing assets can command premium valuations when they have:
regulatory approvals,
strong customers,
complex chemistry,
or valuable product portfolios.
RPG will need to avoid overpaying simply because it wants rapid scale.
Management's emphasis on valuation and expected returns suggests financial discipline remains part of its acquisition framework.
Industry Consolidation Could Create More Opportunities
The Indian API industry remains fragmented.
Many manufacturers operate:
single plants,
specialised chemistry platforms,
or relatively narrow product portfolios.
That fragmentation creates opportunities for larger buyers to consolidate assets.
Companies with capital and professional integration capabilities can potentially build multi-site platforms through acquisitions.
RPG's ₹500 crore-plus capital pool positions it to participate in that consolidation.
Conclusion
RPG Life Sciences is preparing for the next stage of its API expansion after spending ₹215 crore on Actis Generics and Raghava Life Sciences' API business, with more than ₹500 crore of capital now available for larger acquisitions and manufacturing investments.
The two recent transactions have already increased RPG Active Pharma's manufacturing capacity from 110 KL to 505 KL, expanded its commercial portfolio from 14 to 45 products, more than doubled its customer base to over 250, and increased its R&D pipeline from 12 to 28 products.
Management is now evaluating assets that can add differentiated chemistry, international regulatory access, USFDA-approved capabilities, new customers and stronger export potential.
The strategy is broader than simply buying more manufacturing capacity.
RPG wants to build an independent merchant API and advanced-intermediates platform capable of serving domestic and international pharmaceutical customers, while also exploring selected CDMO opportunities.
With committed capital of approximately ₹700 crore, support from InvAscent and a debt-free balance sheet, RPG has the financial flexibility to pursue another round of transactions.
The critical issue will be execution.
If the company can maintain valuation discipline, integrate the businesses successfully and improve utilisation across its enlarged manufacturing base, the current acquisition programme could turn RPG Active Pharma into a substantially larger participant in India's API industry.